X4 is developing and commercializing innovative therapies for those with rare diseases of the immune system. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI™ (mavorixafor). Mavorixafor is also being studied in additional potential indications, including chronic neutropenia.
X4 Pharmaceuticals, Inc. is a global, late-stage clinical biopharmaceutical company. X4 is a leader in the discovery and development of novel therapies for the treatment of rare diseases of the immune system, including WHIM syndrome and chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts with a research center of excellence in Vienna, Austria